Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Presents Data at 2021 International Liver Conference for Wnt-Modulating Antibody SZN-043

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
June 17, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications

SOUTH SAN FRANCISCO, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
June 01, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Publishes Article in Nature Communications Demonstrating Selective Wnt Mimetics Stimulate Bone Mass Accrual in Disease Models of Osteoporosis, Aging and Long-Bone Fracture

Results Demonstrate Rapid and Robust Bone-building Effects from Selective Wnt Agonists in Proof of Concept, Preclinical Studies of Wnt Mimetics for the Treatment of Diseases of Low Bone Mineral...
May 24, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Presents Data from Lead Wnt-Modulating Antibody Programs, SZN-1326 and SZN-043, in Six Oral and Poster Presentations at 2021 Digestive Disease Week Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced...
May 06, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
March 11, 2021 14:37 ET | Source: Surrozen, Inc.

Surrozen Expands Board of Directors with Appointment of Mary Haak-Frendscho, Ph.D.

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
February 02, 2021 18:31 ET | Source: Surrozen, Inc.

Surrozen Expands Board of Directors with Appointment of Shao-Lee Lin, M.D., Ph.D.

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
November 12, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker,...
October 29, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen Appoints Charles Williams as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the appointment of...
October 15, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right